
    <html>
    <head><title>BU.TO</title>
<style>
body {
  font-family: Arial, sans-serif;
  margin: 20px;
}
.container {
  display: grid;
  grid-template-columns: 50% 50%;
  grid-template-rows: auto auto;
  gap: 20px;
}
img {
  width: 100%;
  height: auto;
  max-height: 400px;
  border: 1px solid #ccc;
  object-fit: contain;
}

.cell {
  padding: 10px;
}
.table-scroll {
  max-height: 400px;
  overflow-y: auto;
  border: 1px solid #aaa;
}
table {
  width: 100%;
  border-collapse: collapse;
}
th, td {
  border: 1px solid #aaa;
  padding: 5px;
  text-align: left;
  font-size: 14px;
}
.negative {
  background: linear-gradient(to right, #ffdddd, white);
}
.positive {
  background: linear-gradient(to right, white, #ddffdd);
}
.pos-light  { background: #e6ffe6; }  
.pos-mid    { background: #99ff99; }  
.pos-strong { background: #33cc33; }   

.neg-light  { background: #ffe6e6; }   
.neg-mid    { background: #ff9999; }   
.neg-strong { background: #ff3333; }   

h2 { border-bottom: 2px solid #444; }
<script>
function toggleText(id) {
  const moreText = document.getElementById(id);
  const btn = document.getElementById(id + "_btn");

  if (moreText.style.display === "none") {
    moreText.style.display = "inline";
    btn.innerText = " Show less";
  } else {
    moreText.style.display = "none";
    btn.innerText = " Show more";
  }
}
</script>
</style>
</head>
    <body>
    <h2><span style='color:#1e66f5; font-weight:900; margin-right:10px;'>quarterly earnings d</span> BU.TO  <span style='color:orange; font-weight:800; margin-left:8px;'>nan</span>
        <span style='font-weight:normal; font-size: 18px;'>(5d - annual shareholder meeting)</span>
        <span style='color:black; font-weight:bold; font-size: 20px;'> </span>
        <a href='https://finance.yahoo.com/chart/BU.TO?interval=1mo' target='_blank'>Yahoo</a>
        <span style='font-weight:600;'>  bought (2.83-2.83) —  — now: 2.83</span>
    </h2>

    <div class="container">
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><div class='table-scroll'><table><tr><th>Date</th><th>Score</th><th>AMR</th><th>Type</th><th>Summary</th><th>Links</th></tr><tr class='pos-light'><td>2025-09-11</td><td>0.20</td><td></td><td>product launch</td><td>0.2 local feel              __   BU.TO __    -> i:0.2<-                      <br><br>FEELING: total score 0.2 Reasoning: The news highlights the first commercial sales of a key product (high-purity canola protein). This falls under product launches (0.2 to 0.3). The phrasing "signals potential revenue generation and future growth opportunities" indicates a positive outlook, justifying a score of 0.2. The need to "monitor sales volume and profitability closely" tempers the enthusiasm slightly, preventing a higher score. The rest of the information is descriptive and doesn't carry significant financial implications. --- <br> - Burcon's first commercial sales of high-purity canola protein mark a significant milestone, potentially signaling revenue generation and future growth opportunities for investors. Monitor sales volume and profitability closely. <br><br>*** REZUMAT *** - Burcon NutraScience reports first commercial sales. - High-purity canola protein is the product sold. - Marks a key milestone for the company. - Signals potential revenue generation.   (gemma3:12b-it-q4_K_M on 2025-09-11 22:54:07)</td><td><a href='https://www.msn.com/en-us/money/savingandinvesting/burcon-nutrascience-achieves-first-commercial-sales-of-high-purity-canola-protein/ar-AA1Mhzdb' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-10</td><td>0.20</td><td></td><td>Product launch</td><td>0.2 local feel              __   BU.TO __    -> i:0.2<-                      <br><br>FEELING: total score 0.2 Reasoning: The news highlights the commencement of commercial sales of PurateinC, a new product. This falls under "product launches" which carries a positive score of +0.2 to +0.3. The text emphasizes this as a "significant milestone" and a validation of their growth strategy, suggesting a positive impact. However, the text also mentions the need to "monitor sales volume and customer adoption," which introduces some uncertainty and tempers the initial positive sentiment. Therefore, a score of 0.2 reflects the initial positive launch tempered by the need for ongoing monitoring. --- <br> - Burcon's first commercial sales of PurateinC, a high-purity canola protein isolate, mark a significant milestone and validate their growth strategy. Investors should monitor sales volume and customer adoption of this new product line to assess the long-term impact on revenue growth. <br><br>*** REZUMAT *** - First commercial sales of PurateinC, a 90%+ high-purity canola protein isolate, have commenced. - Sales mark a step in scaling Burcon's innovation into the market. - Puratein C has over 90% protein content and a PDCAAS of 1. - Product is derived from non-GMO canola seeds grown in North America. - Suitable for various food & beverage applications, including meat analogues. - Burcon holds an extensive patent portfolio for plant-based proteins.   (gemma3:12b-it-q4_K_M on 2025-09-10 23:09:08)</td><td><a href='https://www.newsfilecorp.com/release/265814/Burcon-Achieves-First-Commercial-Sales-of-HighPurity-Canola-Protein' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-09-10</td><td>-0.30</td><td></td><td>product launch</td><td>-0.3 local feel              __   BU.TO __    -> i:0.3<-                      <br><br>FEELING: total score -0.3 Reasoning: Product Launches (+0.2): The achievement of first commercial sales of PurateinC is a positive development, indicating a new revenue stream. This gets a moderate positive score. Financial Challenges (-0.3): The news explicitly mentions "significant financial challenges," "recurring losses," and "dependence on external financing." This is a major negative, outweighing the positive product launch. Analyst Ratings (-0.1): The "Sell" technical sentiment from TipRanks and the "Underperform" rating from an AI analyst contribute a slight negative. Low Absolute Value for Publicity: The news is a mix of factual reporting and some promotional language, so the overall impact is tempered. --- <br> - Burcon achieved its first commercial sales of PurateinC, a positive development. However, significant financial challenges and a "Sell" technical sentiment signal from TipRanks suggest caution for investors. <br><br>*** REZUMAT *** - Burcon NutraScience (BU) reports first commercial sales of PurateinC. - PurateinC is a high-purity canola protein isolate (over 90% protein). - Demand for clean-label plant proteins is driving the sales. - TipRanks AI Analyst rates BU as "Underperform" due to financial challenges. - Company faces recurring losses and dependence on external financing. - Current market cap is C$29.69M. - Technical sentiment signal is "Sell". - Average trading volume: 12,728   (gemma3:12b-it-q4_K_M on 2025-09-10 23:10:31)</td><td><a href='https://www.tipranks.com/news/company-announcements/burcon-nutrascience-achieves-first-commercial-sales-of-high-purity-canola-protein' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-09</td><td>0.20</td><td></td><td>Product launches</td><td>0.2 local feel              __   BU.TO __    -> i:0.2<-                      <br><br>FEELING: total score 0.2 Reasoning: The news primarily discusses market growth projections for pea protein, a positive indicator for companies like BU.TO that operate in this space. The projected CAGR of 8.59% between 2025 and 2030 suggests increasing demand and potential revenue growth. This aligns with a product launches and market growth event, warranting a slightly positive score. The mention of key players expanding production capacity further supports this positive outlook. However, the report also includes historical data (2022-2024) which is given a very low absolute score value. The report also mentions competitors, which slightly reduces the positive impact. --- <br> - The pea protein market is poised for significant growth, projected to reach $2.15 billion by 2030 with an 8.59% CAGR. Key players like Roquette and Ingredion are driving innovation and expanding production capacity. Investors should consider the increasing demand for plant-based proteins and sustainable food solutions. <br><br>*** REZUMAT *** - Market to grow from $1.424B in 2025 to $2.150B by 2030. - CAGR of 8.59% expected between 2025 and 2030. - Roquette launched NUTRALYS pea proteins in Feb 2024. - Roquette opened a large pea protein factory in Canada in Nov 2021. - Ingredion introduced Vitessence Pea 100 HD in July 2024. - Ingredion launched VITESSENCE Pulse 1803 in 2023 for EMEA. - Report covers 2022-2024 historical data & 2025-2030 forecast. - Key players profiled: Burcon, Cargill, Cosucra, DuPont, Glanbia, Ingredion, Kerry, Now Health, Roquette, Yutong.   (gemma3:12b-it-q4_K_M on 2025-09-09 22:51:59)</td><td><a href='https://www.globenewswire.com/news-release/2025/09/09/3146654/0/en/Pea-Protein-Market-Forecast-Report-2025-2030-with-Profiles-of-Burcon-NutraScience-Cargill-Cosucra-DuPont-de-Nemours-Glanbia-Ingredion-Kerry-Group-Roquette-Freres-and-Yutong-Industr.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-04</td><td>0.20</td><td></td><td>Product launch</td><td>0.2 local feel              __   BU.TO __    -> i:0.2<-                      <br><br>FEELING: total score +0.2 Reasoning: The news primarily revolves around the achievement of commercial production for Puratein C. This falls under product launches (+0.2 to +0.3). The fact that it's a new product entering a "rapidly expanding plant-based protein sector" suggests potential for future revenue growth, which is a positive signal. The mention of an "extensive patent portfolio" also adds a slight positive element. However, the text emphasizes "market adoption" which introduces some uncertainty, preventing a higher score. The date of production (September 2025) is forward-looking, but not a major catalyst. --- <br> - Burcon's achievement of commercial production for Puratein C, a 90%+ canola protein isolate, marks a significant milestone. This expands their portfolio and demonstrates their ability to scale innovation. Investors should monitor revenue growth and market adoption of this new product within the rapidly expanding plant-based protein sector. <br><br>*** REZUMAT *** - Burcon achieved commercial production of Puratein C canola protein isolate. - Puratein C is 90%+ high-purity canola protein. - Production started on September 4, 2025, at the Galesburg facility. - The protein is derived from non-GMO canola seeds. - It has a PDCAAS of 1 and a complete amino acid profile. - Suitable for food, beverage, nutrition, and nutraceutical applications. - Burcon holds an extensive patent portfolio for plant-based proteins.   (gemma3:12b-it-q4_K_M on 2025-09-05 12:06:32)</td><td><a href='https://www.stocktitan.net/news/BRCNF/burcon-achieves-first-commercial-production-of-puratein-r-c-canola-o7twgihtmgs2.html' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-09-04</td><td>-0.30</td><td></td><td>Product launches</td><td>-0.3 local feel              __   BU.TO __    -> i:0.3<-                      <br><br>FEELING: total score -0.3 Reasoning: Here's a breakdown of the score based on the provided news and the defined events: quarterly or annual results: Not explicitly mentioned, but the news highlights "recurring losses," implying consistently poor financial performance. This contributes negatively. (-0.1) management changes: Not mentioned. (0) guidance updates: Not mentioned. (0) analyst meetings: Analyst rating of "Underperform" from Spark rates contributes negatively. (-0.1) credit rating changes: Not mentioned. (0) buyback programs: Not mentioned. (0) product launches: Commencement of PurateinC production is a positive, but the overall cautious sentiment and financial challenges temper this. (+0.1) capital raises: The news mentions "relies on external financing," suggesting ongoing capital needs, which is a slightly negative signal. (-0.1) technical sentiment signal: "Sell" technical sentiment contributes negatively. (-0.1) The overall cautious tone and the mention of financial challenges outweigh the positive aspect of production commencement. --- <br> - Burcon's commencement of PurateinC production is a positive step, but significant financial challenges and a "Sell" technical sentiment signal from analysts suggest caution for investors. Monitor financial performance closely. <br><br>*** REZUMAT *** - Burcon (TSE:BU) begins commercial PurateinC production at Galesburg facility. - PurateinC is a high-purity canola protein isolate with >90% protein content. - Addresses growing global demand for sustainable protein solutions. - Spark rates TSE:BU as "Underperform" due to financial challenges. - Company faces recurring losses and relies on external financing. - Market Cap: C$31.59M. - Average Trading Volume: 14,039. - Technical Sentiment Signal: Sell.   (gemma3:12b-it-q4_K_M on 2025-09-05 12:26:15)</td><td><a href='https://www.tipranks.com/news/company-announcements/burcon-nutrascience-launches-commercial-production-of-high-purity-canola-protein' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-04</td><td>0.30</td><td></td><td>Product launch</td><td>0.3 local feel              __   BU.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Reasoning: Product Launches (0.2 to 0.3): The achievement of commercial production for PurateinC canola protein is a significant product launch. The description highlights its potential in food, beverage, and nutraceutical applications, suggesting strong market potential. Revenue Streams (0.1): The news explicitly mentions expanding revenue streams, which is a positive indicator for future financial performance. Backward-looking data/Publicity (0): The news contains some backward-looking information (e.g., patent portfolio), but the primary focus is on the forward-looking achievement of commercial production. The score is not higher because the news doesn't explicitly mention financial impact (e.g., sales projections, profitability). The success of the product will depend on market adoption and integration into Burcon's portfolio, which are not guaranteed. --- <br> - Burcon's achievement of commercial production for PurateinC canola protein is a significant milestone, demonstrating their ability to scale innovation and expand revenue streams. Investors should monitor the company's ability to capitalize on the growing demand for plant-based proteins and successfully integrate this new product into their portfolio. <br><br>*** REZUMAT *** - Burcon achieved commercial production of PurateinC canola protein. - Production began at the Galesburg facility. - PurateinC is a 90%+ high-purity canola protein isolate. - The protein is derived from non-GMO canola seeds. - It has a PDCAAS of 1 and a complete amino acid profile. - The process upcycles canola oilseed processing by-products. - The protein is suitable for food, beverage, and nutraceutical applications. - Burcon holds an extensive patent portfolio for plant-based proteins.   (gemma3:12b-it-q4_K_M on 2025-09-05 12:27:24)</td><td><a href='https://www.newsfilecorp.com/release/265100/Burcon-Achieves-First-Commercial-Production-of-PurateinRC-Canola-Protein' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-09-03</td><td>-0.30</td><td>5</td><td>annual shareholder meeting</td><td>-0.3 local feel              __   BU.TO __    -> i:0.5<-                     **   ** 2025-09-17 **   <br><br>** 2025-09-17  annual shareholder meeting ***<br>FEELING: total score -0.3 Reasoning: Here's a breakdown of the scoring based on the provided news and the defined events: Significant financial challenges and recurring losses reported: -0.2 (This directly indicates financial distress, triggering a negative score.) "Sell" technical signal: -0.1 (Technical signals, while not purely financial, can influence investor sentiment and are considered here.) Proposed warrant amendment: 0 (Warrant amendments can be complex, and without knowing the full implications, it's neutral.) TipRanks AI rates TSE:BU as "Underperform": -0.05 (Analyst ratings receive a low score unless there's a clear consensus. This is a single rating.) Market cap currently at C$33.24M: Very low absolute score value (Backward-looking data, irrelevant to future prospects.) Focus on plant-based protein innovation for food/beverage: Very low absolute score value (Promotional language, not directly impactful.) Extensive patent portfolio for novel plant-based proteins: Very low absolute score value (Backward-looking data, irrelevant to future prospects.) The negative factors (financial challenges, "Sell" signal) outweigh the neutral and low-impact elements. --- <br> - Burcon faces financial challenges and a "Sell" technical signal, despite promising customer projects. Investors should proceed with caution, monitoring the warrant amendment vote and the company's ability to address its financial position. <br><br>*** REZUMAT *** - Annual shareholder meeting scheduled for September 17, 2025. - Over 150 customer projects nearing final evaluation. - Proposed warrant amendment: exercise price to $3.50/share. - TipRanks AI rates TSE:BU as "Underperform." - Significant financial challenges and recurring losses reported. - Market cap currently at C$33.24M. - Technical sentiment signal: "Sell." - Focus on plant-based protein innovation for food/beverage. - Extensive patent portfolio for novel plant-based proteins. - Average trading volume: 13,952   (gemma3:12b-it-q4_K_M on 2025-09-04 05:57:02)</td><td><a href='https://www.tipranks.com/news/company-announcements/burcon-nutrascience-prepares-for-annual-shareholder-meeting-with-key-warrant-amendments' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-01</td><td>0.30</td><td></td><td>quarterly earnings</td><td>0.3 local feel              __   BU.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Breakdown: quarterly or annual results: While the news mentions "impacted financials" due to one-time costs, the reaffirmed targets for revenue growth and positive cash flow by 2026 suggest a slightly positive outlook. Score: +0.1 major dividend change: Not applicable. Score: 0 mergers/acquisitions: Not applicable. Score: 0 management changes: Not applicable. Score: 0 guidance updates: The reaffirmed revenue target and positive cash flow projection by 2026 can be interpreted as a form of guidance. Score: +0.2 stock splits: Not applicable. Score: 0 share consolidations: Not applicable. Score: 0 lawsuits: Not applicable. Score: 0 accretive to DCF per share: Not explicitly mentioned, but the reaffirmed targets and growth projections imply potential for future accretion. Score: +0.1 debt restructuring / renegotiation: Not applicable. Score: 0 credit rating changes: Not applicable. Score: 0 buyback programs: Not applicable. Score: 0 FDA or Canada Health decisions: Not applicable. Score: 0 product launches: The success at the IFT trade show and customer response to plant proteins can be considered a positive product-related development. Score: +0.1 capital raises: Not applicable. Score: 0 bankruptcy filings or Chapter 11 protection: Not applicable. Score: 0 strategic partnerships or joint ventures: The multiyear production agreement can be considered a strategic partnership. Score: +0.1 analyst meetings: Not applicable. Score: 0 large contract wins or losses: The $6.8 million multiyear production agreement is a significant contract win. Score: +0.3 cybersecurity incidents / data breaches: Not applicable. Score: 0 major political actions like war or major strikes: Not applicable. Score: 0 regulatory changes: Not applicable. Score: 0 --- <br> - Burcon's earnings call showcased optimism driven by successful production milestones, strong customer response, and a multiyear agreement. While onetime costs impacted financials, reaffirmed targets for revenue growth and positive cash flow by 2026 suggest a positive outlook for investors. <br><br>*** REZUMAT *** - Q1 earnings call highlighted advancements in production and customer engagement. - Successful integration at Galesburg facility enabled commercial production of Peazazz & fava protein. - Customer response to plant proteins (pea & fava) exceeded expectations. - Secured $6.8 million multiyear production agreement. - IFT trade show success demonstrated appeal in plant-based cheese. - Reaffirmed 2025 revenue target: $1-$3 million. - Projects double-digit revenue growth & positive cash flow by 2026. - High onetime start-up costs impacted Q1 financials.   (gemma3:12b-it-q4_K_M on 2025-09-04 15:09:25)</td><td><a href='https://www.tipranks.com/news/company-announcements/burcon-nutrascience-optimism-in-earnings-call' target='_blank'>Link</a></td></tr></table></div></div>
    </div>
    </body>
    </html>
    